Recent Finacing
Recent Raise
Palladio Biosciences develops lixivaptan, a selective vasopressin V2 receptor antagonist for ADPKD; completed Phase 2 and is enrolling a Phase 3 liver‑safety ALERT trial for patients intolerant to tolvaptan.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Palladio Biosciences.
